Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study-论文-万方医学网

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study

导出原文传递

翻译打印收藏纠错

作者： Friedrich, Christian ^[1] ; Francke, Klaus ^[2] ; Gashaw, Isabella ^[3] ; Scheerans, Christian ^[4] ; Klein, Stefan ; Fels, Lueder ; Smith, Jaclyn A. ; Hummel, Thomas ; Morice, Alyn

作者单位： Pharmaceut Clin Pharmacol,Bayer AG Res & Dev ^[1] Manchester Univ NHS Fdn Trust,Univ Manchester ^[2] Dept Otorhinolaryngol,Tech Univ Dresden ^[3] Ctr Clin Sci,Univ Hull ^[4]

关键词 CHRONIC COUGH ENDOMETRIOSIS MANAGEMENT NEUROPATHY GUIDELINE RESPONSES WOMEN PAIN ATP

发布时间 2022-10-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study

相似文献

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study

相似文献

相关期刊

检索历史清除